Display options
Share it on

Indian J Clin Biochem. 2014 Oct;29(4):442-51. doi: 10.1007/s12291-013-0379-z. Epub 2013 Sep 15.

Administering the Optimum Dose of l-Arginine in Regional Tumor Therapy.

Indian journal of clinical biochemistry : IJCB

Emad Y Moawad

Affiliations

  1. Faculty of Engineering, Ain Shams University, Cairo, Egypt ; 217 Alhegaz Street, Alnozha, Cairo, 11351 Egypt.

PMID: 25298625 PMCID: PMC4175696 DOI: 10.1007/s12291-013-0379-z

Abstract

The purpose of this study is optimizing the l-arginine (l-Arg) doses on the basis of chemical structure in regional accessible tumor therapy to settle down a new protocol for the treatment of cancer. (3)H-thymidine-based cell proliferation assay was performed in vitro on tumor cell lines of fibrosarcoma (FS), lymphosarcoma-ascitic and on normal cell line of NIH 3T3 after treatment with different concentrations of l-Arg in phosphate buffered saline (PBS). The cultures were harvested after 22 h and the incorporated radioactivity was counted to identify their histologic grades as described in earlier studies. In vivo therapy of murine tumors was conducted where FS cells injected subcutaneously at ventro-lateral position of mice. Various drug delivery schedules were injected into the centre of tumor base, once a day for 4 days. Tumor diameter and survivals were monitored where the day of sacrifice was considered for monitoring the survival period. By identifying the histologic grades of the treated cultures in vitro and in vivo by different concentrations of l-Arg, the corresponding energy of such concentrations were determined. An efficient model with a good fit (R(2) = 0.98) was established to describe the energy yield by l-Arg dose. The equivalence between the tumor histologic grade and energy of the l-Arg dose delivered in saline (PBS) environment is the optimum condition for regional tumor therapy achieves higher survival rate. The selective cytotoxicity to tumor cells with minimal damage to normal cells by l-Arg due to its chemical structure suggests to be considered the most promising drug for regional therapy of the accessible tumors like breast cancers of early stage with no distant metastasis.

Keywords: 3H-thymidine-based cell proliferation assay; 51Chromium release assay; Cell membrane damage; Emad formula; Histologic grade; Stimulating apoptosis

References

  1. Cancer Nanotechnol. 2011;2(1-6):81-93 - PubMed
  2. Cancer Immunol Immunother. 2005 Sep;54(9):837-47 - PubMed
  3. Nutr Clin Pract. 2005 Feb;20(1):52-61 - PubMed
  4. Clin Nutr. 2009 Feb;28(1):65-70 - PubMed
  5. Cancer Res. 2005 Feb 1;65(3):913-8 - PubMed
  6. Acta Pharmacol Sin. 2005 Aug;26(8):992-9 - PubMed
  7. Arch Biochem Biophys. 2010 Jan 15;493(2):213-20 - PubMed
  8. Mol Pharmacol. 2007 Jan;71(1):276-83 - PubMed
  9. Syst Synth Biol. 2012 Dec;6(3-4):61-8 - PubMed
  10. Cancer Nanotechnol. 2012;3(1-6):37-46 - PubMed
  11. Nucl Med Mol Imaging. 2010 Jun;44(2):123-36 - PubMed
  12. J Natl Cancer Inst. 1980 Nov;65(5):909-12 - PubMed
  13. Oncogene. 2002 Feb 14;21(8):1251-62 - PubMed
  14. Biomed Pharmacother. 2002 Nov;56(9):439-45 - PubMed
  15. J Appl Toxicol. 2004 Mar-Apr;24(2):93-7 - PubMed
  16. Wound Repair Regen. 2003 Nov-Dec;11(6):419-23 - PubMed

Publication Types